<?xml version="1.0" encoding="UTF-8"?>
<p>Other secondary efficacy endpoints were duration of fever [defined as time to return to afebrile state (≤37.2°C)], duration of all symptoms, time to return to normal health and activity, frequency of influenza-related complications (all of which were predefined and required investigator confirmation: death, hospitalization, pneumonia, bronchitis, sinusitis, otitis media, encephalitis/encephalopathy, febrile seizures or myositis) and proportion of children requiring antibiotics.</p>
